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Abstract
Background—Sphincter of Oddi dysfunction (SOD) is a controversial topic, especially in 
patients with no objective findings on laboratory or imaging studies (SOD type III). The value of 
ERCP manometry with sphincterotomy is unproven and carries significant risks.
Objective—To describe the process of planning and initiating a randomized sham-controlled 
study to establish whether patients with SOD respond to sphincter ablation, and whether the 
outcomes are predicted by the pain patterns, presence or absence of other functional GI or 
psychosocial problems, or the results of manometry.
Design—Planning a trial to establish which patients with “suspected SOD” (if any) respond to 
endoscopic sphincter ablation.
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Setting—Meetings and correspondence by a planning group of gastroenterologists and clinical 
research specialists hosted at the Medical University of South Carolina.
Patients—Clarifying subject characteristics and inclusion and exclusion criteria.
Interventions—Defining the questionnaires, therapies, randomizations, and numbers of subjects 
required by outcome measures. Defining the metrics of success and failure.
Results—The planning resulted in funding for the proposed study as a cooperative agreement 
with the National Institute of Diabetes and Digestive and Kidney Diseases.
Limitations—Lack of data required several consensus decisions in designing the protocol.
Conclusion—The planning process was challenging, and some changes were needed after 
initiation.* (Clinical trial registration number: NCT00688662.) (Gastrointest Endosc 
2010;72:986-91.)
Sphincter of Oddi dysfunction (SOD) encompasses a spectrum of disorders in which 
stenosis or spasm of the biliary and/or pancreatic sphincters results in episodes of abdominal 
pain.1-6 The diagnosis is often considered in patients who have undergone cholecystectomy. 
Patients with few or no laboratory or imaging abnormalities (ie, SOD type III) are very 
difficult to evaluate and to manage effectively.7 Imaging tests can exclude other pathologies, 
but there are no simple diagnostic tests for SOD. ERCP is usually considered when 
noninvasive diagnostic avenues have been explored and after trials of medical therapies. The 
purpose is to check that there are no subtle structural abnormalities in the papilla, biliary 
tree, or pancreas and to perform sphincter of Oddi manometry (SOM)2,8 and possible 
sphincterotomy. There are several major outstanding issues. Although two randomized 
controlled trials in patients with SOD type II have shown that the results of SOM are 
somewhat predictive of the outcome of biliary sphincterotomy,9,10 this has never been 
proven in type III patients. An important problem in this context is that ERCP (with or 
without SOM) carries significant risks, especially pancreatitis.11,12 Another issue is that 
many patients suspected of having SOD also have symptoms of more generalized digestive 
dysfunction (eg, irritable bowel syndrome), and problems with anxiety or depression.13,14 
Whether their presence predicts the results of treatment aimed at the sphincter has not been 
established. Furthermore, assessment of treatment outcomes is made difficult by the known 
placebo response to sham interventions.4,5,9,10 All of these facts mandate the need for more 
research, as recommended by the latest deliberations of the Rome committee.15
We received a planning grant from the National Institute of Diabetes and Digestive and 
Kidney Diseases in 2004 to explore appropriate designs for a comprehensive clinical study 
to test the primary hypothesis that some patients with SOD respond to sphincterotomy. The 
EPISOD (Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction) study 
was funded in June 2007, and recruitment began in 6 U.S. centers late in 2008. The present 
commentary discusses the challenges in planning and starting the study.
DEFINING THE STUDY POPULATION
A fundamental issue was to define the study population. We used the clinical definition of 
SOD recently updated by the Rome III committee,15 with some points of clarification.
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Although SOD may occur in patients with intact gall bladders, attributing the pain 
specifically to sphincter dys-function in that context is doubly difficult. We limited the study 
population to patients with persistent or recurrent pain after cholecystectomy (and after >3 
months to get baseline data).
Pain burden issues
Pain is the major symptom of SOD, and its relief is the main potential benefit of treatment. 
Measuring pain burden proved to be challenging. Standard pain scoring instruments16,17 are 
not suitable in SOD, where pains may be intermittent and vary in severity. We found an 
analogy in the Migraine Disability Assessment instrument developed in the context of 
migraine headaches.18 In collaboration with the codeveloper of the Migraine Disability 
Assessment, Dr Stewart, we developed and tested an analogous instrument, Recurrent 
Abdominal Pain Intensity and Disability (RAPID).19 By using this instrument, we defined a 
minimum amount of baseline abdominal pain-related disability that was considered to be 
sufficient to justify the risks of ERCP intervention. The eligibility criterion was set at grade 
3, which translates into ≥12 days of lost time because of abdominal pain episodes from paid 
work or school, household work, or nonwork activities over the preceding 3 months.
Rome III included “no daily pain” as a new criterion in their definition of SOD, in an 
attempt to separate this syndrome from other functional GI disorders. However, many 
patients presenting with “suspected SOD” do have some symptoms every day as well as 
episodes of disabling pain, so it was agreed to allow daily “discomfort” if <3 in severity on a 
scale of 1 to 10.
Excluding structural disease
To exclude other pathologies and overlap syndromes, subjects must have a negative upper 
endoscopy (and negative testing or prior treatment for Helicobacter pylori), and abdominal 
scans showing no structural lesion. The acceptable size of the bile duct after 
cholecystectomy is a controversial topic, but we settled on a diameter of ≤9 mm.
Laboratory findings
The Rome criteria for biliary SOD include the need for normal amylase and lipase, but add 
that elevated liver tests with pain episodes may be supportive. The goal of the study was to 
address the most controversial group of patients, ie, those with normal liver tests. However, 
slight elevations of transaminases are common, partly because of the prevalence of fatty 
liver disease, so the study allowed transaminases up to twice the upper limit of normal, 
provided that the elevation was not in the context of a pain exacerbation that normalizes 
afterward. The Rome criteria for pancreatic SOD state that amylase/lipase must be 
elevated.15 However, referral centers performing large numbers of SOM procedures 
commonly find elevated pancreatic sphincter pressures in patients in whom amylase/lipase 
have been consistently normal.
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SOD (as judged by SOM abnormality) is found in many patients with recurrent and chronic 
pancreatitis.2,5 We excluded anyone with a definite history of acute or chronic pancreatitis 
to focus on SOD as a cause of pain.
Trials of medical therapy
To ensure that simple methods had been exhausted, we required trials of acid-suppression 
medications and anti-spasmodics. Anyone taking antidepressants had to be on a stable dose.
Other exclusion criteria
Patients who had previously undergone any sphincter therapy or surgery involving biliary 
diversion were excluded from the study. Enrollment was limited also to subjects aged 18 to 
65 years. Although SOD occurs in children, it is rare. In patients aged >65 years, there is 
increasing likelihood of finding other pathology, such as tumors, and of confusing 
comorbidities. To exclude the possibility of narcotic bowel syndrome, and to avoid the 




Scheduling staff at each site reviewed referring materials to identify patients with pain and 4 
basic criteria, ie, age 18 to 65 years, postcholecystectomy, and with no prior sphincter 
treatment or pancreatitis. These materials are then reviewed by clinical staff for the other 
inclusion/exclusion criteria (Table 1). Patients who appeared to be eligible were educated 
about the study and invited to participate. If they agreed, they signed a comprehensive 
consent document and then completed questionnaires to assess the presence of significant 
psychiatric illness and other functional digestive disorders. These issues were explored with 
the Mini International Neuropsychiatric Interview,20 Hospital Anxiety and Depression,21 
Coping Strategies Questionnaire–Catastrophizing Subscale,22 Trauma Questionnaire–Short 
Form,23 Beck Depression Inventory,24 and the Short Form 36.25 If no exclusion criteria 
emerged, subjects were enrolled and proceeded to ERCP.
ERCP
ERCP was performed in the standard manner under conscious sedation or anesthesia. The 
type and amount of medications that could be given before manometry was defined, and 
their doses were recorded. A pancreatogram was obtained to rule out pancreas divisum (an 
exclusion criterion), and manometry was performed (at least for the pancreatic sphincter) by 
standard water-perfused technique. Abnormality was defined as a basal pressure of >40 mm 
Hg in both leads, sustained for ≥30 seconds.
Sphincterotomy allocation
Treatment in this study meant endoscopic sphincterotomy at the time of ERCP, but there are 
two sphincters. Although closely related, the biliary and pancreatic sphincters can yield 
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discordant readings,6 so it is necessary to clarify whether treatment is aimed at either one 
separately, or at both. The simplest study design to answer the question would be to have 3 
arms, ie, sham, biliary sphincterotomy alone, and dual (biliary and pancreatic) 
sphincterotomy, regardless of the manometry results. We felt that it is ethical to allow 
biliary sphincterotomy in the face of normal sphincter pressures (which often occur in 
practice), but pancreatic sphincterotomy carries greater short-and long-term risks. We 
addressed this problem by a two-stage randomization. The initial allocation was to sham or 
sphincterotomy regardless of the manometry results. Then, those patients assigned to 
sphincterotomy and who were found to have elevated pancreatic sphincter pressures were 
randomized again to biliary sphincterotomy or to both biliary and pancreatic 
sphincterotomy.
Treatment allocation was done centrally by using a validated clinical trials data management 
system referred to as WebDCU. For the rare case that the website could not be accessed, an 
emergency randomization envelope was available in the endoscopy suite.
Pancreatic stenting
All patients in the study received a small (3F or 4F) temporary pancreatic stent to reduce the 
risk of post-procedure pancreatitis.12 These passed spontaneously over a few days or weeks, 
as confirmed by abdominal radiographs.
Post-ERCP care, blinding, and follow-up
Subjects were admitted for overnight observation. To avoid assessment bias, especially 
because the outcomes (pain severity and impact/disability) can be somewhat subjective, the 
EPISOD subjects and their caregivers were blinded to the treatment allocation until the end 
of the study. Because the ERCP was grant funded, patients did not receive a bill for their 
procedure. Subjects were followed by phone calls at monthly intervals for a year by a study 
coordinator blinded to the treatment allocation.
DEFINING SUCCESS AND FAILURE
The primary goal of the study was to see whether patients respond to sphincter ablation. 
This meant deciding what level of improvement constitutes success and after what time 
interval. Patients had to be at grade 3 disability on the RAPID instrument to enter the study. 
Success was defined as a RAPID grade of 1 (mildly limiting or no disability) at both 9 and 
12 months after randomization. Failure was defined as a RAPID grade >1 at month 9 or 12 
after randomization, an increase in narcotic use, or recommendation for repeated 
intervention.
To eliminate bias in the decisions about reintervention, each site designated an evaluating 
physician who was not one of the treating physicians for the study. Patients unhappy with 
their progress consulted with the evaluating physician, who was blinded to the treatment 
allocation but had all other study clinical data, including the sequential RAPID scores. The 
evaluating physician could recommend continuing medical treatment or referral back to a 
treating physician at that site for consideration of repeated ERCP and treatment. This 
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recommendation defined failure, even if the treating physician disagreed and declined 
intervention at that time.
SAMPLE SIZE
For reasons of ethics and statistical power, and to encourage participation in the trial, a 2:1 
randomization ratio was chosen in favor of sphincterotomy. This proportion of 
sphincterotomy to no sphincterotomy mimics the chance of getting a sphincterotomy in 
standard clinical practice, when the decision is made based on SOM and about two-thirds of 
patients have positive SOM.
Studies with sham arms have shown a ~30% placebo response rate.4,5,18,19 A clinically 
relevant absolute difference in success rates between the two interventions (sham vs 
sphincterotomy) was chosen at 30% (success ratesham = 30%; success ratesphc = 60%). The 
study was powered to assure >90% likelihood of identifying a difference in success rates 
≥30%. Sample size estimation was based on the comparison of independent proportions with 
a 2:1 (sphincterotomy:sham) randomization scheme. The maximum sample size required for 
randomization was 192 subjects (128 in treatment and 64 in sham group). Assuming a 10% 
rate for subjects who drop out or are lost to follow-up, a total of 214 subjects was required 
for randomization. This number was increased to 250 because of anticipated loss of 15% of 
subjects at the time of ERCP as a result of finding pancreas divisum or failing pancreatic 
SOM. Thus, a total of 250 SOD III patients were to be enrolled in the study.
ECONOMICS OF SOD
SOD is a common and costly condition for which an effective early treatment may be 
expected to improve patients’ future quality of life and to reduce the cost of medical care for 
their remaining lifetime. The EPISOD economic analysis will evaluate the economic impact 
of endoscopic sphincterotomy in patients with SOD. We will calculate incremental cost-
effectiveness ratios and cost increases/cost offsets caused by the differences in therapy.
SAFETY ISSUES
An independent Data and Safety Monitoring Board appointed by and advisory to the 
National Institute of Diabetes and Digestive and Kidney Diseases reviewed and made 
recommendations on the original study design and is currently monitoring the study. A 
Medical Safety Monitor was appointed to review serious adverse events as they occur and 
advise the National Institute of Diabetes and Digestive and Kidney Diseases and the Data 
and Safety Monitoring Board on any safety concerns that require prompt attention. In 
addition, serious adverse events are reported to the clinical coordinating center and the 
Institutional Review Board at the site where the event occurs.
Adverse events judged to be related to the ERCP procedure are documented by using a 
standard lexicon.26 All others occurring during the year of follow-up are defined and graded 
by the Common Terminology Criteria for Adverse Events system in use in cancer trials.27 
The costs of any complications are not covered by the grant, and this is clearly stated in the 
consent process.
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ANCILLARY STUDY: EPISOD 2
Recognizing that some eligible patients may not accept randomization, a naturalistic follow-
up study referred to as EPISOD 2 allows consenting patients to be followed for 12 months in 
the same way as those in the main study, after “standard” manometry-directed therapy. This 
will provide additional valuable information about treatment response, and also about the 
relationships between the response and the presence or absence of other functional and 
psychiatric disorders.
CHALLENGES AFTER THE STUDY COMMENCED
Approximately 12 months after the first site was initiated, 507 patients had been 
prescreened. Of the 87 who appeared to be eligible, 65 consented to the study. Thirty-one of 
these were ineligible after final screening: 25 were randomized, and 8 were entered into 
EPISOD 2. This inadequate accrual rate led to discussion about the reasons.
Analysis of the screen failure log showed that the 4 most common reasons for ineligibility 
were liver tests slightly out of range, elevations of amylase/lipase, daily pain, and daily 
narcotic use. After extensive discussion, the Data and Safety Monitoring Board approved 
some relaxation of the first 3 criteria. Liver test limits were raised to direct bilirubin and 
alkaline phosphatase <2× normal, transaminases <3× normal, and amylase/lipase to <3× 
normal. The increases in the lab test limits were thought to be justified because minor 
elevations were common and often not sustained. The daily pain exclusion in Rome III was 
eliminated after discussion with the chair of the Rome project. There is no evidence that 
daily pain excludes the diagnosis of SOD or successful treatment, and including this 
category would provide useful data on those points. The daily narcotic use exclusion 
remained in place.
The second key issue was publicity, which has been addressed aggressively by multiple 
methods, including through professional organizations, brochures at meetings, letters to 
referring physicians, and internet advertising.
To enhance recruitment further, two more sites were added, and additional funding was 
approved to increase the time available for coordinators to screen proactively.
Abbreviations
RAPID Recurrent Abdominal Pain Intensity and Disability instrument
SOD sphincter of Oddi dysfunction
SOM sphincter of Oddi manometry
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• Designing and initiating a randomized sham-controlled trial of patients with 
“suspected sphincter of Oddi dysfunction” after cholecystectomy required close 
collaboration between relevant interested endoscopists and established clinical 
researchers. There were particular challenges in defining the precise 
characteristics of subjects to be studied, and the criteria for success and failure. 
Initial slow recruitment led to the need for extensive publicity, some small 
changes in the protocol, and additional treatment sites.
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TABLE 1
Eligibility criteria (protocol changes in italics)
Inclusion criteria
    1. Age 18-65 years.
    2. Patients diagnosed with the clinical syndrome of SOD, as defined by the Modified Functional Biliary Disorders Module of the Rome III 
criteria.
    3. Pain burden of grade 3 or higher on RAPID questionnaire.
    4. Cholecystectomy >90 days before enrollment.
    5. Laboratory tests: Results within 1 week before the baseline visit and any others available from the preceding 6 months 
(postcholecystectomy):
            Direct bilirubin, alkaline phosphatase, amylase, and lipase results must be within normal limits. Changed to <2× upper limit normal 
(ULN).
            Transaminases <2× ULN. Changed to <3× ULN.
    6. Normal abdominal imaging by CT or MR/MRCP with bile duct ≤9 mm.
    7. Upper endoscopy without findings to explain the pain, with negative testing for H pylori, or recent treatment.
    8. Trial of acid suppressant medications and antispasmodics.
    9. Subjects on antidepressants for pain control (not required) should be taking them for ≥1 month before the baseline assessment.
    10. Patients with depressive and/or anxiety disorders who receive psychopharmacologic treatment must be on stable dose for ≥6 weeks.
    11. The total number of days in the previous 3 months that the subject had taken prescription analgesics because of episodes of abdominal 
pain is not greater than the total number of days the subject had episodes of pain.
Exclusion criteria
    Pre-ERCP exclusion criteria
        1. Prior ERCP treatment.
        2. Pregnancy.
        3. Prior gastric resection or surgery involving biliary diversion.
        4. Prior diagnosis of acute pancreatitis.
        5. Daily use of prescription analgesics over the previous month.
        6. Daily abdominal discomfort every day for the past month at a level of 3 or more on a scale of 1-10. This criterion was eliminated.
        7. Significant psychiatric disorders:
            a. Lifetime psychotic disorders, bipolar disorder.
            b. Substance use disorders within 6 months.
            c. Eating disorders within 2 years.
            d. Moderate and severe depression (see text).
            e. Suicidal risk.
        8. Any condition that makes the subject unsuitable for study participation.
    ERCP exclusion criteria
        1. Pancreas divisum.
        2. Any pathology found at ERCP (except sphincter hypertension).
        3. Failed pancreatic manometry.
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